hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site
hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
Signet Therapeutics gets FDA IND approval for sigx1094 in diffuse gastric cancer
Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)'s Investigational New Drug (IND) approval of ... Read More
Agenus announces promising trial results for colon cancer treatment at ESMO Congress
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled promising results from an investigator-sponsored trial (IST) ... Read More
ENCell announces promising results from Phase 1 CMT1A trial of EN001
ENCell Co., Ltd., a South Korean biotech leader specializing in Cell and Gene Therapy (CGT), has unveiled promising results from their first-in-human Phase 1 clinical ... Read More
PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced a significant milestone in the development of ... Read More
Medidata unveils Clinical Data Studio to transform clinical trials
Medidata, a Dassault Systèmes brand and a key player in clinical trial solutions for the life sciences industry, today announced the launch of Medidata Clinical ... Read More
Enveda Biosciences secures $55m to advance AI-driven drug discovery
Enveda Biosciences, a leader in utilizing artificial intelligence (AI) to convert nature’s chemistry into groundbreaking medicines, has successfully raised an additional $55 million. This funding ... Read More
RemeGen’s RC88 shows promising results in Phase I/II study for advanced solid tumors
RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class ... Read More